Literature DB >> 23189327

Median tests for censored survival data; a contingency table approach.

Shaowu Tang1, Jong-Hyeon Jeong.   

Abstract

The median failure time is often utilized to summarize survival data because it has a more straightforward interpretation for investigators in practice than the popular hazard function. However, existing methods for comparing median failure times for censored survival data either require estimation of the probability density function or involve complicated formulas to calculate the variance of the estimates. In this article, we modify a K-sample median test for censored survival data (Brookmeyer and Crowley, 1982, Journal of the American Statistical Association 77, 433-440) through a simple contingency table approach where each cell counts the number of observations in each sample that are greater than the pooled median or vice versa. Under censoring, this approach would generate noninteger entries for the cells in the contingency table. We propose to construct a weighted asymptotic test statistic that aggregates dependent χ(2)-statistics formed at the nearest integer points to the original noninteger entries. We show that this statistic follows approximately a χ(2)-distribution with k-1 degrees of freedom. For a small sample case, we propose a test statistic based on combined p-values from Fisher's exact tests, which follows a χ(2)-distribution with 2 degrees of freedom. Simulation studies are performed to show that the proposed method provides reasonable type I error probabilities and powers. The proposed method is illustrated with two real datasets from phase III breast cancer clinical trials.

Entities:  

Mesh:

Year:  2012        PMID: 23189327      PMCID: PMC4281497          DOI: 10.1111/j.1541-0420.2011.01723.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  9 in total

1.  Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation.

Authors:  Bernard Fisher; Jong-Hyeon Jeong; Stewart Anderson; John Bryant; Edwin R Fisher; Norman Wolmark
Journal:  N Engl J Med       Date:  2002-08-22       Impact factor: 91.245

2.  A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES.

Authors:  E A GEHAN
Journal:  Biometrika       Date:  1965-06       Impact factor: 2.445

3.  Nonparametric inference on median residual life function.

Authors:  Jong-Hyeon Jeong; Sin-Ho Jung; Joseph P Costantino
Journal:  Biometrics       Date:  2007-05-14       Impact factor: 2.571

4.  An approximate distribution of estimates of variance components.

Authors:  F E SATTERTHWAITE
Journal:  Biometrics       Date:  1946-12       Impact factor: 2.571

5.  Nonparametric estimation for the difference or ratio of median failure times.

Authors:  J Q Su; L J Wei
Journal:  Biometrics       Date:  1993-06       Impact factor: 2.571

6.  Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study.

Authors:  P J Hoskins; K D Swenerton; J A Pike; F Wong; P Lim; C Acquino-Parsons; N Lee
Journal:  J Clin Oncol       Date:  2001-10-15       Impact factor: 44.544

7.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

Authors:  David Cunningham; Yves Humblet; Salvatore Siena; David Khayat; Harry Bleiberg; Armando Santoro; Danny Bets; Matthias Mueser; Andreas Harstrick; Chris Verslype; Ian Chau; Eric Van Cutsem
Journal:  N Engl J Med       Date:  2004-07-22       Impact factor: 91.245

8.  A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.

Authors:  B Fisher; J Costantino; C Redmond; R Poisson; D Bowman; J Couture; N V Dimitrov; N Wolmark; D L Wickerham; E R Fisher
Journal:  N Engl J Med       Date:  1989-02-23       Impact factor: 91.245

9.  Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083.

Authors:  M C Perry; J E Herndon; W L Eaton; M R Green
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544

  9 in total
  4 in total

1.  Stability of nocturnal wake and sleep stages defines central nervous system disorders of hypersomnolence.

Authors:  Kiran P Maski; Alicia Colclasure; Elaina Little; Erin Steinhart; Thomas E Scammell; William Navidi; Cecilia Diniz Behn
Journal:  Sleep       Date:  2021-07-09       Impact factor: 6.313

2.  Comparing survival curves based on medians.

Authors:  Zhongxue Chen; Guoyi Zhang
Journal:  BMC Med Res Methodol       Date:  2016-03-16       Impact factor: 4.615

3.  Artificial Intelligence to Get Insights of Multi-Drug Resistance Risk Factors during the First 48 Hours from ICU Admission.

Authors:  Inmaculada Mora-Jiménez; Jorge Tarancón-Rey; Joaquín Álvarez-Rodríguez; Cristina Soguero-Ruiz
Journal:  Antibiotics (Basel)       Date:  2021-02-27

4.  Survival, costs, and health care resource use by line of therapy in US Medicare patients with newly diagnosed glioblastoma: a retrospective observational study.

Authors:  Abdalla Aly; Prianka Singh; Beata Korytowsky; You-Li Ling; Hrishikesh P Kale; Homa B Dastani; Marc F Botteman; Andrew D Norden
Journal:  Neurooncol Pract       Date:  2019-09-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.